<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04611100</url>
  </required_header>
  <id_info>
    <org_study_id>111/2562</org_study_id>
    <nct_id>NCT04611100</nct_id>
  </id_info>
  <brief_title>Efficacy of Intraductal Radiofrequency Ablation in Combination With Metallic Biliary Stenting in Advanced Hilar Cholangiocarcinoma</brief_title>
  <official_title>Efficacy of Intraductal Radiofrequency Ablation in Combination With Metallic Biliary Stenting in Advanced Hilar Cholangiocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rajavithi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rajavithi Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aim to evaluate the efficacy of intraductal radiofrequency ablation for unresetable&#xD;
      hilar cholangiocarcinoma in addition to biliary stenting. The patient would be randomized&#xD;
      into 1:1 ratio of conventional group who received biliary stenting alone, and RFA group who&#xD;
      receive intraductal RFA before biliary stenting. Immediate complications as well as long term&#xD;
      stent patency and patient survival would be studied.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design: randomized single-blind control trial Study population: patient with&#xD;
      unresectable hilar cholangiocarcinoma with obstructive jaundice who need hilar biliary&#xD;
      stenting Primary endpoint: Biliary stent patency time Secondary endpoint: Patient survival&#xD;
      Intervention&#xD;
&#xD;
        1. Recruited patients randomly assigned into 2 groups, conventional and RFA group by sealed&#xD;
           enveloped&#xD;
&#xD;
        2. All patients receive endoscopic biliary stenting. Those in RFA group receive RFA before&#xD;
           biliary stent.&#xD;
&#xD;
        3. Monitor for adverse event during hospitalization and during follow up&#xD;
&#xD;
        4. Follow up as outpatient in 4-weekly interval with monitoring of serum liver function&#xD;
           test as routine&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biliary stent patency</measure>
    <time_frame>up to 6 months</time_frame>
    <description>The duration between primary intervention and first recurrent increased in serum total bilirubin after intervention up to 6 months after the primary procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient survival</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Survival time after primary intervention and documented patient death at 6 months after primary intervention</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Hilar Cholangiocarcinoma</condition>
  <condition>Biliary Obstruction</condition>
  <arm_group>
    <arm_group_label>Conventional</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patient receive endoscopic placement of metallic biliary stent for obstructive jaundice</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiofrequency ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient receive endoscopic intraductal radiofrequency ablation before placement of biliary stent for obstructive jaundice</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ELRA endoluminal radiofrequency ablation electrode (Taewoong, Seoul, Korea)</intervention_name>
    <description>Intraductal radiofrequency ablation using ELRA endoluminal radiofrequency ablation electrode (Taewoong, Seoul, Korea) 10W 2 minutes at the obstructed bile duct before placing uncover self-expandable biliary metal stent</description>
    <arm_group_label>Radiofrequency ablation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Hilar cholangiocarcinoma diagnosed by imaging or pathology&#xD;
&#xD;
          -  Considered unresectable or unfit for surgery&#xD;
&#xD;
          -  Presence of obstructive jaundice need endoscopic biliary drainage&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of unremovable metallic biliary stent placement&#xD;
&#xD;
          -  severe biliary stricture that the instrument was unable to pass through&#xD;
&#xD;
          -  unfit for endoscopic under conscious sedation&#xD;
&#xD;
          -  loss to follow up and loss contact within 6 months after intervention&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tanyaporn Chantarojanasiri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rajavithi hospital, Bangkok, Thailand</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tanyaporn Chantarojanasiri, md</last_name>
    <phone>66898104033</phone>
    <email>chtunya@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rajavithi Hospital</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <reference>
    <citation>Sripa B, Pairojkul C. Cholangiocarcinoma: lessons from Thailand. Curr Opin Gastroenterol. 2008 May;24(3):349-56. doi: 10.1097/MOG.0b013e3282fbf9b3. Review.</citation>
    <PMID>18408464</PMID>
  </reference>
  <reference>
    <citation>Doherty B, Nambudiri VE, Palmer WC. Update on the Diagnosis and Treatment of Cholangiocarcinoma. Curr Gastroenterol Rep. 2017 Jan;19(1):2. doi: 10.1007/s11894-017-0542-4. Review.</citation>
    <PMID>28110453</PMID>
  </reference>
  <reference>
    <citation>Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, Zhu AX, Murad MH, Marrero JA. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018 Jan;67(1):358-380. doi: 10.1002/hep.29086.</citation>
    <PMID>28130846</PMID>
  </reference>
  <reference>
    <citation>Kim JH, Won HJ, Shin YM, Kim PN, Lee SG, Hwang S. Radiofrequency ablation for recurrent intrahepatic cholangiocarcinoma after curative resection. Eur J Radiol. 2011 Dec;80(3):e221-5. doi: 10.1016/j.ejrad.2010.09.019. Epub 2010 Oct 14.</citation>
    <PMID>20950977</PMID>
  </reference>
  <reference>
    <citation>Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet. 2014 Jun 21;383(9935):2168-79. doi: 10.1016/S0140-6736(13)61903-0. Epub 2014 Feb 26. Review.</citation>
    <PMID>24581682</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 4, 2020</study_first_submitted>
  <study_first_submitted_qc>October 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 2, 2020</study_first_posted>
  <last_update_submitted>October 30, 2020</last_update_submitted>
  <last_update_submitted_qc>October 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hilar cholangiocarcinoma</keyword>
  <keyword>Biliary obstruction</keyword>
  <keyword>Radiofrequency ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Klatskin Tumor</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

